Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

Table 5 Comparison of responders and virological non-responders to antiviral therapy

Parameter	Responders (n = 3271)	Non-responders (n = 171)	P value
Gender, females/males, n (%)	1539 (47)/1732 (53)	42 (24.6)/129 (75.4)	< 0.0001
Age (yr), mean ± SD; min-max	58.0 ± 12.6; 21-97	55.0 ± 10.5; 29-84	0.0002
Females	61.6 ± 11.8; 21-91	59.9 ± 10.6; 35-81	0.3173
Males	54.8 ± 12.4; 21-97	53.4 ± 10; 29-84	0.1045
BMI, mean ± SD; min-max	27.4 ± 5.0; 13.4-57.4	28.7 ± 4.6; 16-47.5	0.0001
Current treatment regimen
Genotype-specific treatment regimens
ASV + DCV	47 (1.4)	8 (4.7)	0.0001
LDV/(SOF ± RBV)	748 (22.9)	30 (17.5)	0.1047
OBV/PTV/(r ± DSV ± RBV)	1052 (32.2)	24 (14)	< 0.0001
GZR/(EBR ± RBV)	387 (11.8)	11 (6.4)	0.0314
Pangenotypic regimens
GLE/PIB	420 (12.8)	15 (8.8)	0.1186
GLE/(PIB + SOF + RBV)	2 (0.1)	0	0.7464
SOF/(VEL ± RBV)	477 (14.6)	44 (25.7)	0.0001
VOX/VEL/SOF	7 (0.2)	0	0.5448
GT, n (%)			< 0.0001
1	63 (1.9)	2 (1.2)
1a	70 (2.2)	1 (0.6)
1b	2624 (80.2)	89 (52.0)
3	397 (12.1)	76 (44.4)
4	110 (3.4)	3 (1.8)
Other	7 (0.2)	0
Comorbidities, n (%)
Any comorbidity	2498 (76.4)	131 (4)	0.9425
Hypertension	1533 (46.9)	66 (2)	0.0345
Diabetes	731 (22.3)	46 (1.4)	0.1651
Renal disease	124 (3.8)	8 (0.2)	0.5558
Autoimmune diseases	63 (1.9)	0	0.0670
Non-HCC tumors	68 (2.1)	6 (0.2)	0.1963
Other	1783 (54.5)	96 (2.9)	0.6762
Concomitant medications, n (%)	2389 (73.0)	136 (79.5)	0.0610
Treatment experienced	1039 (31.8)	69 (40.4)	0.0208
History of hepatic decompensation, n (%)
Ascites	297 (9.0)	21 (12.2)	0.1588
Encephalopathy	65 (2.0)	7 (4.1)	0.0606
Documented esophageal varices, n (%)	780 (23.8)	64 (37.4)	0.0001
Hepatic decompensation at baseline, n (%)	173 (5.3)	18 (10.5)	0.0035
HCC history, n (%)	117 (3.6)	9 (5.3)	0.2523
OLTx history, n (%)	28 (0.9)	1 (0.6)	0.7052
Child-Pugh class, n (%)
B or C	296 (9)	29 (17)	0.0006
HBV coinfection (HBsAg+), n (%)	50 (1.5)	2 (1.2)	0.7075
HIV coinfection, n (%)	79 (2.4)	6 (3.5)	0.3690
ALT IU/L, mean ± SD	101.2 ± 80.8	106.9 ± 82.0	0.3385
Bilirubin mg/dL, mean ± SD	1.1 ± 0.9	1.2 ± 0.7	< 0.0001
Albumin g/dL, mean ± SD	4.5 ± 7.7	3.9 ± 3.1	0.0002
Creatinine mg/dL, mean ± SD	0.9 ± 2.3	0.8 ± 0.2	0.8562
Hemoglobin g/dL, mean ± SD	14.1 ± 1.8	13.9 ± 1.8	0.1319
Platelets, × 1000/μL, mean ± SD	132.6 ± 66.8	109.2 ± 59.4	< 0.0001
HCV RNA × 106 IU/ml, mean ± SD	2.2 ± 10.0	2.0 ± 2.9	0.1123

SD: Standard deviation; BMI: Body mass index; ASV: Asunaprevir; DCV: Daclatasvir; LDV: Ledipasvir; SOF: Sofosbuvir; RBV: Ribavirin; OBV: Ombitasvir; PTV/r: Paritaprevir; DSV: Dasabuvir; GZR: Grazoprevir; EBR: Elbasvir; GLE: Glecaprevir; PIB: Pibrentasvir; VEL: Velpatasvir; VOX: Voxilaprevir; GT: Genotype; HCC: Hepatocellular carcinoma; OLTx: Orthotopic liver transplantation; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HIV: Human immunodeficiency virus; ALT: Alanine transaminase; HCV RNA: Ribonucleic acid of hepatitis C virus.